2. Antibody-drug Conjugate/ADC Related Immunology/Inflammation
  3. Antibody-Drug Conjugates (ADCs) TROP2
  4. Sacituzumab tirumotecan

Sacituzumab tirumotecan  (Synonyms: SKB264; MK-2870)

Cat. No.: HY-164789 Purity: 97.82%
COA
SDS
Handling Instructions Technical Support

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer.

For research use only. We do not sell to patients.

Sacituzumab tirumotecan

Sacituzumab tirumotecan Chemical Structure

CAS No. : 2768350-77-0

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Sacituzumab tirumotecan Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer[1][2][3].

In Vitro

Sacituzumab tirumotecan binds to human TROP2 protein with an EC50 of 2.787 ng/ml, similar to its monoclonal antibody[2].
Sacituzumab tirumotecan binds to TROP2-positive HCC1806 and NCI-N87 cells with EC50 values of 11.21 nM and 6.213 nM, respectively[2].
Sacituzumab tirumotecan (72 h) inhibits the growth of TROP2-positive HCC1806, NCI-N87, BxPC-3, Calu-3, and NCI-H23 (TROP2+) cells with IC50 values of 1.281-18.83 nM[2].
Sacituzumab tirumotecan (50 μg/ml; 144 h) is stable in human and cynomolgus monkey plasma, with 70% payload release after 144 h of incubation at 50 μg/ml[2].
Sacituzumab tirumotecan (0.0823-2.22 nM; 120 s association, 600 s dissociation) binds to human TROP2 protein with a Kd value of 0.3083 nM[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sacituzumab tirumotecan Related Antibodies
Parmacokinetics
Species Dose Route T1/2 Tmax Cmax AUC0-t AUC0-∞
Cynomolgus Monkey[2] 1 mg/kg i.v. 23.8 h 0.178 h 25.2 μg/mL 787 μg·h/mL 792 μg·h/mL
Cynomolgus Monkey[2] 3 mg/kg i.v. 24.8 h 0.261 h 77.4 μg/mL 2170 μg·h/mL 2250 μg·h/mL
Cynomolgus Monkey[2] 10 mg/kg i.v. / 0.425 h 25.2 μg/mL 8550 μg·h/mL 8640 μg·h/mL
In Vivo

Sacituzumab tirumotecan (SKB264) (1-10 mg/kg; i.v.; twice weekly; 6 times) exhibits dose-dependent antitumor efficacy in the HCC1806 breast cancer CDX model, with TGI ranging from 75.6% to 105.0% at tested doses[2].
Sacituzumab tirumotecan (SKB264) (1-10 mg/kg; i.v.; twice weekly; 6 times) exhibits stronger antitumor efficacy than IMMU-132 at the same doses in the HCC1806 breast cancer CDX model[2].
Sacituzumab tirumotecan (SKB264) (0.3-3 mg/kg; i.v.; twice weekly; 6 times) exhibits dose-dependent antitumor efficacy in the NCI-N87 gastric carcinoma CDX model, with TGI ranging from 78.4% to 151.2% at tested doses[2].
Sacituzumab tirumotecan (SKB264) (0.5-5 mg/kg; i.v.; twice weekly; 6 times) exhibits dose-dependent antitumor efficacy in the BR1282 breast cancer PDX model, with TGI ranging from 44.0% to 104.8% at tested doses[2].
Sacituzumab tirumotecan (SKB264) (1-10 mg/kg; i.v.; twice weekly; 6 times) is effective in TROP2-positive gastric carcinoma PDX models (IHC ≥1+), with TGI >100% at 3 mg/kg in tested positive models[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude (female)[2]
Dosage: 1, 3, 10 mg/kg
Administration: i.v.; twice weekly; 6 times
Result: Reported tumor growth inhibition (TGI) of 75.6% (1 mg/kg), 98.5% (3 mg/kg), and 105.0% (10 mg/kg) on day 24 after first dose.\nReported tumor growth inhibition (TGI) of 81.06% (1 mg/kg), 189.46% (3 mg/kg), and 188.86% (10 mg/kg) on day 21 after treatment initiation; these values were higher than corresponding doses of IMMU-132.
Animal Model: BALB/c nude (female)[2]
Dosage: 0.3, 1, 3 mg/kg
Administration: i.v.; twice weekly; 6 times
Result: Reported tumor growth inhibition (TGI) of 78.4% (0.3 mg/kg), 139.2% (1 mg/kg), and 151.2% (3 mg/kg) on day 24 after first dose.
Animal Model: BALB/c nude[2]
Dosage: 0.5, 1.5, 5 mg/kg
Administration: i.v.; twice weekly; 6 times
Result: Reported tumor growth inhibition (TGI) of 44.0% (0.5 mg/kg), 92.6% (1.5 mg/kg), and 104.8% (5 mg/kg) on day 24 after first dose.
Animal Model: NCG[2]
Dosage: 1, 3, 10 mg/kg
Administration: i.v.; twice weekly; 6 times
Result: Achieved tumor growth inhibition (TGI) exceeding 100% at 3 mg/kg in all three TROP2-positive models (0406022, A11068, 0501116); observed no antitumor effect in the TROP2-negative model (A19058) at 3 mg/kg.
Molecular Weight

157907 (average)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Sacituzumab tirumotecan]
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light
Purity & Documentation

Purity: 97.82%

SDS (251 KB)

COA (231 KB) Others (112 KB) SEC-HPLC (205 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sacituzumab tirumotecan Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sacituzumab tirumotecan2768350-77-0SKB264 MK-2870SKB 264SKB-264MK2870MK 2870MK-2870Antibody-Drug Conjugates (ADCs)TROP2Antibody-Drug ConjugatesEGP-1M1S1GA733-1cynomolgus monkeysDNA damagetopoisomerase Inon-small cell lung cancerTROP2-positive tumor cellsapoptosisG2/S cell cycle arrestHR+/HER2? breast cancermetastatic triple-negative breast cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sacituzumab tirumotecan
Cat. No.:
HY-164789
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.